ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,018.39
-0.34%
US Tech 100
16,860.80
0.00%
다우존스 지수
37,903.29
0.23%
Bitcoin
57,647.02
-1.01%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) 뉴스

IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:IONS
일자시간출처헤드라인심볼기업
2024/04/2520:00PR Newswire (US)Ionis Publishes 2023 Corporate Responsibility ReportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/04/2320:05PR Newswire (US)Ionis to hold first quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
2024/04/0722:48PR Newswire (US)Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
2024/04/0120:05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/2820:05PR Newswire (US)Ionis to hold olezarsen Phase 3 data webcastNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/2521:18PR Newswire (US)Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/1320:00PR Newswire (US)Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASHNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0621:30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0509:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0509:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0509:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0509:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0509:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/2923:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/2923:05PR Newswire (US)Ionis announces new chief global product strategy officer to lead next phase of commercial growthNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/2821:05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/2201:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/2121:00PR Newswire (US)Ionis reports fourth quarter and full year 2023 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/2100:39Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/1709:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/1706:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/1521:00PR Newswire (US)Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/1500:04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/1320:09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/0821:00PR Newswire (US)Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathyNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/0721:05PR Newswire (US)Ionis to hold fourth quarter and full year 2023 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/0309:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/0309:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/0309:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/0309:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:IONS

최근 히스토리

CCOM
US500
US 500
FX
USDEUR
US Dollar vs Euro
AMEX
XLV
Health Care Select Sector
COIN
BTCUSD
Bitcoin
PM
XAUUSD
Gold vs US Dollar
COIN
SOLUSD
Solana
NYSE
JPM
JP Morgan Chase
USOTC
RHHBY
Roche (QX)
COIN
ETHUSD
Ethereum
AMEX
SPY
SPDR S&P 500
NASDAQ
MSFT
Microsoft
NASDAQ
AMZN
Amazon.com
NYSE
CVX
Chevron
USOTC
BASFY
BASF (QX)
NYSE
BAC
Bank of America
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유